Register
Alirocumab reduces cardiac events after acute coronary syndrome |
Journal Updates
eMediNexus Coverage from: 
Alirocumab reduces cardiac events after acute coronary syndrome
eMediNexus,  13 March 2018
remove_red_eye 638 Views
#Cardiology #Internal Medicine #Pharmacist

1 Read Comments                

The proprotein convertase subtilisin-kexin 9 (PCSK9) inhibitor alirocumab was shown to reduce the rates of major adverse cardiovascular events (MACE) by 15% compared with placebo in patients with persistently high cholesterol despite high-intensity statin therapy, according to a study presented March 10, 2018 at the American College of Cardiologys 67th Annual Scientific Session in Orlando, Florida.


Comments

Comments on eMediNexus are moderated. We retain the right to remove any comments at our sole discretion.